Patients with bipolar disorder may be prescribed Lithium for long-term mood stabilisation and relapse prevention. It helps regulate manic and depressive episodes, while treatment requires individual dosing and regular blood monitoring because lithium levels can become toxic.
Lithium is a pharmaceutical mood stabiliser used mainly in bipolar disorder. It is recognised as a first-line option for long-term maintenance therapy and prophylaxis of bipolar disorders, especially when the aim is to reduce repeated manic, hypomanic, or depressive episodes.
Unlike standard antidepressants, Lithium is not intended to lift mood in isolation. Unlike an acute antipsychotic, it is often used over a longer period to reduce the risk of future mood episodes. NICE guidance places lithium among the key treatments considered for bipolar disorder maintenance, with treatment decisions based on clinical history, kidney function, thyroid status, age, and other medicines [1].
Lithium tablets require careful clinical management. The dose is decided individually, taking age, other medicines, and health conditions into account.
Lithium has two important roles in bipolar disorder: helping control certain acute mood episodes and preventing recurrence during maintenance treatment. Its long-term value is linked to relapse reduction and a lower risk of suicide in people with bipolar disorder, although individual response varies.
The treatment plan depends on the phase of illness:
| Treatment phase | Clinical role of Lithium | Main monitoring focus |
|---|---|---|
| Acute mania | May be used to reduce manic symptoms, sometimes alongside an antipsychotic | Blood concentration, kidney function, hydration |
| Bipolar depression | May form part of a wider treatment plan where clinically appropriate | Mood response, suicidal thinking, interactions |
| Long-term maintenance | Helps reduce recurrence of manic and depressive episodes | Regular lithium levels, thyroid and kidney tests |
Lithium is not a rapid sedative. Acute mania may require another psychiatric medicine while Lithium is being established. Antipsychotics can be used alongside it when agitation, psychosis, or severe mania requires faster symptom control.
The World Health Organization recognises bipolar disorder as a condition requiring continuing care, relapse prevention, and attention to suicide risk. The American Psychiatric Association also describes mood stabilisers as central to long-term bipolar disorder management. Lithium may be selected when a clinician wants a maintenance treatment with evidence across both manic and depressive relapse prevention.
A useful clinical distinction is the difference between symptom control and prophylaxis. Symptom control addresses the episode happening now. Prophylaxis means reducing the chance of future episodes after improvement has occurred.
Lithium acts as a mood stabiliser in the brain and helps regulate biological processes involved in manic and depressive episodes. Its pharmacological effects support longer-term prevention of both manic and depressive relapse, although the precise mechanism is complex and individual response varies.
Lithium may be unsuitable or require specialist management in people with:
Lithium is not suitable for everyone. Not for you if treatment cannot be monitored safely because regular blood testing is unavailable, kidney function is significantly impaired, or fluid intake cannot be kept consistent. The treatment requires a careful assessment before initiation and continued monitoring during use.
Pregnancy does not automatically exclude lithium, but the decision requires individual assessment because fetal and maternal considerations change across pregnancy. Breastfeeding also requires a specialist discussion because lithium passes into breast milk and the infant may need monitoring.
Do not stop Lithium suddenly without medical direction. Abrupt discontinuation can increase the risk of relapse, especially after long-term maintenance treatment. A planned reduction may be appropriate in some circumstances, but the timing and pace depend on the clinical situation.
Common lithium-related effects include fine hand tremor, increased thirst, increased urination, nausea, loose stools, weight change, tiredness, and a metallic taste. Some effects are most noticeable during the first weeks and may settle after dose adjustment.
Tremor can be more troublesome after caffeine, stress, or poor sleep. Taking the prescribed tablets consistently and avoiding sudden changes in caffeine or fluid intake can make symptoms easier to assess. Persistent tremor may indicate that the dose or blood concentration needs review.
Longer-term treatment can affect the thyroid and kidneys. Lithium may contribute to hypothyroidism, which can cause tiredness, cold intolerance, dry skin, constipation, or low mood. Kidney monitoring is used to identify changes before they become clinically significant.
Seek urgent medical assessment for signs of possible lithium toxicity, including:
A person can become toxic even when the prescribed dose has not changed. Fever, heavy exercise in hot weather, gastroenteritis, or a newly added interacting medicine can alter lithium levels.
Lithium medicines contain lithium in a pharmaceutical formulation. The exact formulation and prescribed regimen should be considered when interpreting treatment and monitoring results. The dose is decided individually, taking age, other medicines, kidney function, hydration, health conditions, and treatment response into account.
Lithium dosing is started and adjusted according to the person’s diagnosis, age, kidney function, concurrent medicines, treatment response, and blood concentration. The dose is decided individually, taking age, other medicines, and health conditions into account.
Treatment commonly involves:
The blood sample must be taken at the clinically specified time in relation to the previous dose. A level taken too soon after a tablet can be misleading. Patients often miss this detail when attending a morning blood test, so the sampling time should be agreed clearly with the prescribing team.
Never take an extra tablet to compensate for a missed dose unless the prescribing team has given that instruction. Taking two doses close together can increase the concentration without improving mood control.
Lithium toxicity can develop when the dose is unchanged but the body loses water or sodium, or when another medicine reduces lithium clearance [2].
Lithium is a prescription mood stabiliser used mainly for long-term maintenance and relapse prevention in bipolar disorder. Unlike an acute treatment used only to control immediate symptoms, it is commonly monitored over time with blood concentration, kidney function, and thyroid assessments.
Several practical mistakes can make Lithium harder to manage:
A further mistake is judging treatment after only a few days. Maintenance benefit may take time to assess, while adverse effects can appear earlier. Symptom tracking with sleep, mood, tremor, and gastrointestinal symptoms gives the prescriber more useful information than a general statement that the medicine feels different.
In clinical practice, psychiatrists usually describe Lithium as a maintenance treatment rather than a quick symptom reliever. The aim is to reduce the frequency, severity, or duration of future mood episodes while preserving day-to-day functioning.
A doctor will usually want a complete list of prescribed medicines, over-the-counter painkillers, supplements, recent illnesses, and changes in fluid intake. Kidney and thyroid results influence whether treatment can start, continue, or needs adjustment.
Consistent timing helps clinicians interpret both symptom changes and blood results. Taking tablets at irregular times can create confusion about whether a problem reflects the medicine, the illness, or an incorrect blood-sampling interval.
Lithium treatment also works best when early warning signs are recognised. Reduced need for sleep, rapid speech, unusual spending, racing thoughts, or a sudden drop in activity may indicate an emerging mood episode. Early reporting allows the treatment plan to be reviewed before symptoms become severe.
Stopping Lithium suddenly can increase the risk of a manic, depressive, or mixed relapse, especially after long-term treatment. NICE bipolar disorder guidance published in 2023 recommends planned withdrawal when discontinuation is clinically appropriate, with monitoring for returning symptoms. The tapering schedule depends on treatment duration, relapse history, current mood, and the reason for stopping. A prescriber may also arrange follow-up after discontinuation because relapse can occur after the medicine is withdrawn. Follow-up should address mood changes, sleep, and early warning signs.
Some people notice changes in agitation, sleep, or mood stability during the early treatment period, while the full maintenance benefit takes longer to assess. The NHS explains in guidance available in 2025 that lithium requires blood-test-guided adjustment because the useful concentration differs between individuals. A lack of immediate improvement does not necessarily mean the treatment will fail. Persistent symptoms, worsening mood, or suicidal thoughts require prompt clinical review rather than self-adjustment.
Pregnancy and breastfeeding require an individual risk-benefit assessment. The Royal College of Psychiatrists advises in guidance available in 2025 that lithium may be considered in pregnancy for some people, especially where relapse risk is substantial, but monitoring and specialist planning are needed. Lithium can pass into breast milk, so breastfeeding decisions should involve the psychiatric and maternity teams. Do not stop treatment abruptly after discovering a pregnancy.
Weight gain can occur with Lithium, although the degree varies between individuals. The British Association for Psychopharmacology describes in its 2016 guideline weight, thyroid function, appetite, and activity as relevant issues during long-term mood-stabiliser treatment. Weight changes may also reflect improved appetite after recovery from depression or the effects of other medicines taken alongside Lithium. Regular weight review and attention to eating patterns can help identify a trend early.
Older adults may receive Lithium, but treatment often begins cautiously because kidney function and water balance can change with age. The British National Formulary advises in guidance accessed in 2025 careful dosing and monitoring in older people, especially when diuretics, blood-pressure medicines, or anti-inflammatory drugs are also used. Signs of toxicity may be mistaken for confusion, weakness, or unsteadiness related to ageing. New neurological symptoms should therefore be reported promptly.
A lack of improvement may reflect an insufficient treatment period, an unsuitable blood concentration, a different mood disorder, an interacting medicine, or another medical problem. NICE guidance updated in 2023 supports reviewing diagnosis, adherence, blood results, physical health, and concurrent treatment when response is inadequate. The prescriber may adjust the plan or add another psychiatric treatment, depending on the symptoms. Increasing the dose independently is unsafe because toxicity can develop before mood benefit appears.
Before treatment, the clinical team usually reviews kidney function, thyroid function, cardiovascular history, hydration, sodium balance, pregnancy possibility where relevant, and all current medicines. The MHRA's 2017 advice recommends clear arrangements for lithium monitoring, communication between services, and patient education. The prescriber should also know about recurrent vomiting or diarrhoea, low-salt diets, heavy sweating, and use of ibuprofen or diuretics. These details can affect lithium concentrations and treatment safety.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Lithium helped reduce the sharp swings in my mood over several months. I still had some hand tremor at the prescribed dose, and the regular blood tests were inconvenient, but the steadier routine was worth discussing with my psychiatrist.
After I had been taking the tablets consistently for a few weeks, my sleep pattern and day-to-day concentration became more manageable. The change was gradual rather than dramatic, but I felt more stable at work and was satisfied with the result.
Lithium gave me a more predictable baseline over the months I used it. I appreciated that the treatment plan included regular checks, because it made changes in thirst, urination, and tremor easier to put into context.
